After more than a century of active research uric acid has gained the stage as of one of the most reliable candidates for the huge amount of residual cardio-metabolic risk.
o Are all the patients with elevated serum uric acid levels the same?
o What is the threshold level for “cardio-metabolic” hyperuricemia?
o How to identify the patients at risk of cardio-metabolic disease?
o What about in children and adolescents?
o What are the differences with cardiovascular complicated gout?
o What are the preventive/ therapeutic strategies?
o What is the role of ULT?
o What advantages/harm of the use of non-ULT drugs affecting uric acid?
o What is the current position of Guidelines?
The involvement of uric acid in the pathophysiology of hypertension, diabetes and metabolic syndrome particularly at younger ages support the importance of the research in this area. The interaction between genetics, biochemistry, epidemiology and lifestyle is the engine that has boosted the worldwide interest for uric acid and cardio-metabolic disease.
Now is time to move from academy to clinical practice since we urgently need a reliable tool for the identification of which patients deserve something more that theory and hypothesis.
The 4th edition of the Bologna meeting will be focused on the patient with the goal to discuss several burning topics: